Characteristics | |
Age years | 63±14 |
Males | 94 (51) |
NYHA FC % (I/II/III/IV) | 1.1/35.0/59.0/4.9 |
6MWD m | 397±117 |
History of VTE | 135 (73) |
Associated medical conditions | |
Splenectomy | 18 (9.8) |
Pacemaker/indwelling catheter | 22 (12.0) |
Myeloproliferative disorder | 3 (1.6) |
APS | 7 (3.8) |
Lung function tests | |
TLC % pred | 90.7±15.2 |
FVC % pred | 99.7±21.9 |
FEV1 % pred | 89.1±20.1 |
DLCO % pred | 61.2±13.6 |
Haemodynamics | |
Systolic PAP mmHg | 75.6±17.5 |
Diastolic PAP mmHg | 24.5±7.4 |
Mean PAP mmHg | 44.1±9.8 |
Mean RAP mmHg | 8.3±4.0 |
PAWP mmHg | 9.6±3.5 |
Cardiac output L·min−1 | 4.89±1.30 |
Cardiac index L·min−1·m−2 | 2.71±0.64 |
PVR dyn·s·cm−5 | 610±255 |
SvO2 % | 62.2±7.2 |
PAH therapy | |
sGC stimulator | 59 (32.1) |
ERA | 73 (39.7) |
PDE5-I | 47 (25.5) |
Prostacyclin analogue | 13 (7.1) |
Medications % (none/single/double/triple) | 38.0/26.6/28.3/7.1 |
Indication for BPA | |
Clot inaccessibility | 149 (81.0) |
Unfavourable risk–benefit ratio for PEA | 16 (8.7) |
Refusal of PEA | 4 (2.2) |
Post-PEA | 15 (8.2) |